Bristol Myers Squibb Co (BMY) · Oct 29, 2026 · Earnings
Beat — Non-GAAP EPS $1.35 vs ~$1.10 consensus; revenue $13.1B vs ~$12.73B
Bristol Myers’ Q3 earnings beat expectations and revenue guidance rose, but full-year EPS guidance was cut after a larger acquired-IPR&D charge.
Bristol Myers is rebuilding its growth portfolio ahead of heavy dependence on Eliquis and Opdivo, with newer oncology, hematology, cardiovascular and neuroscience products expected to offset maturing legacy brands. That portfolio transition remains the central business story.
The quarter beat the published bar cleanly. Revenue reached $13.1 billion versus a published consensus of about $12.73 billion, while non-GAAP EPS was $1.35 versus roughly $1.10 expected. The filing shows the Growth Portfolio rising 12% year over year to $7.7 billion, led by Eliquis, Camzyos, Reblozyl and Breyanzi.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Revenue (Financial Performance) | $13.1B | $12.2B | ~$12.73B |
| Non-GAAP diluted EPS (Financial Performance) | $1.35 | $1.63 | ~$1.10 |
| Growth Portfolio revenue (Growth Portfolio revenues) | $7.7B | $6.9B | |
| Eliquis revenue (Cardiovascular product summary) | $4.69B |
The operating momentum is better than the headline EPS trend suggests. Growth products are expanding at a double-digit pace, Eliquis revenue is expected to grow 20% to 25% for the full year, and management lifted full-year revenue guidance to roughly $49.75 billion-$50.25 billion from $49.0 billion-$50.0 billion. The increase reflects year-to-date strength rather than a newly announced strategic pivot.
The catch is a sizable EPS guide reset. Full-year non-GAAP EPS guidance fell to $6.35-$6.55 from $6.75-$7.00, even as revenue guidance rose. The filing attributes the change largely to a $0.58-per-share Q3 impact from acquired in-process research and development and licensing income, versus a prior full-year assumption of only $0.02. This is partly accounting and acquisition timing rather than evidence that the commercial engine weakened, but it still lowers the earnings outlook investors had been carrying.
The pipeline story is advancing, but remains execution-dependent. Bristol Myers highlights positive pivotal readouts for Zenbexus, admilparant, RYZ101 and arlo-cel, alongside upcoming ASH data and additional regulatory milestones. That supports the company’s effort to replace future patent-exposed revenue, but the filing provides milestone updates rather than new quantitative evidence of eventual commercial scale. 〔0〕
Bottom line: This was a genuine quarterly earnings beat with stronger revenue momentum and a modestly higher sales outlook. The business trend improved, but the lower EPS guide makes the overall message mixed rather than cleanly positive; the next proof point is whether the pipeline can convert into durable growth beyond Eliquis and Opdivo dependence.
ASH data updates for Zenbexus and golcadomide
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!